抗体偶联药物在小细胞肺癌治疗中的研究进展  

Advances in the study of antibody⁃coupled drugs in the treatment of small cell lung cancer

作　　者：郭梦雅 刘颖[1] 蔡若雪 陈越 胡舒怡 方瑛 周国仁[1] GUO Mengya;LIU Ying;CAI Ruoxue;CHEN Yue;HU Shuyi;FANG Ying;ZHOU Guoren(Department of Oncology,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing Jiangsu 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院/江苏省肿瘤医院/江苏省肿瘤防治研究所肿瘤科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2024年第4期405-410,共6页Chinese Journal of Surgical Oncology

基　　金：江苏省卫健委科研项目重点项目(ZD2021019)。

摘　　要：小细胞肺癌(SCLC)恶性程度高,复发率高,易早期转移,预后较差。对于SCLC患者,标准的治疗方法是放疗联合化疗,治疗策略极其有限。抗体偶联药物(ADCs)是一种由抗体、载体和连接体组成的新型药物,结合了化疗的杀伤作用和靶向治疗的精准性。目前,已广泛应用于乳腺癌的治疗,在SCLC治疗方面的相关研究也在蓬勃开展,主要涉及的靶点有δ样配体3(DLL⁃3)、神经细胞黏附分子56(CD56)、人滋养细胞表面抗原2(TROP⁃2)和B7同系物3(B7⁃H3)。近年来,ADCs在治疗SCLC方面也取得了初步疗效,显示出良好的抗肿瘤活性,有望为SCLC患者提供一种新的治疗选择。Small cell lung cancer(SCLC)has high malignant degree,high recurrence rate,early metastasis,and poor prognosis.For SCLC patients,the standard treatment is radiotherapy combined with chemotherapy,and the treatment strategies are limited.Antibody⁃drug conjugates(ADCs)are novel drugs consisting of antibodies,carriers and linkers,which perfectly combine the killing effect of chemotherapy and the precision of targeted therapy.ADCs have been widely used in the treatment of breast cancer,and the related research in the treatment of SCLC is also booming,mainly involving delta⁃like ligand 3(DLL⁃3),cluster of differentiation 56(CD56),trophoblast cell⁃surface antigen 2(TROP⁃2)and B7 homologue 3(B7⁃H3).In recent years,ADCs have also achieved preliminary efficacy in the treatment of SCLC,showing good anti⁃tumor activity,which is expected to provide a new therapeutic option for SCLC patients.

关 键 词：抗体偶联药物 肺癌 小细胞肺癌 靶向 研究进展 

分 类 号：R734.2[医药卫生—肿瘤]